| Item type |
学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
Successful Treatment with Pembrolizumab of a Patient with Advanced Non-small Cell Lung Cancer Containing a Spindle Cell Carcinoma Component |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Non-small cell carcinoma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
PD-L1 |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
pembrolizumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
sarcomatoid carcinoma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
spindle cell carcinoma |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Yazawa, Nana
Niho, Seiji
Kuninobu, Takuya
Goto, Yuto
Suzuki, Tomonari
Nishimura, Noriaki
Hara, Shohei
Uchida, Nobuhiko
Tei, Rinna
Masawa, Meitetsu
Kushima, Yoshitomo
Nakamura, Yusuke
Okutomi, Hiroaki
Soda, Sayo
Ikeda, Naoya
Arai, Ryo
Takemasa, Akihiro
Shimizu, Yasuo
Nakazato, Yoshimasa
|
| 書誌情報 |
en : Dokkyo Medical Journal
巻 2,
号 2,
p. 170-174,
発行日 2023-06-25
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Pulmonary sarcomatoid carcinoma accounts for 0.1%-0.5% of all lung cancers. It has an aggressive biological behavior and is often resistant to conventional chemotherapy and radiation therapy. An 84-year-old man presented with a painful mass in the left breast. Physical examination revealed two palpable subcutaneous nodules on the back. Computed tomography (CT) scan revealed a 4-cm mass in the upper lobe of the right lung and mediastinal lymphadenopathy. Positron emission tomography (PET) /CT scan revealed excessive FDG hyperaccumulation in the right pulmonary mass, left breast mass, subcutaneous nodules on the back, left second rib, and third thoracic vertebra. Histopathological examination of a needle biopsy specimen obtained from the breast mass revealed atypical spindle cell proliferation with numerous mitoses. Immunohistochemical examination revealed positive staining of the tumor cells for CAM 5.2, and the Ki-67 positive rate was 70%. The patient was diagnosed with non-small cell lung carcinoma containing a spindle-cell carcinoma component, cT4N2M1c, stage IVB. The PD-L1 (22C3) tumor proportion score was 90%. The patient received pembrolizumab 200 mg every three weeks with a partial response. He has continued to receive pembrolizumab for over one year. Further studies on a large number of patients are warranted to evaluate the efficacy of PD-1/PD-L1 inhibitor therapy for pulmonary sarcomatoid carcinoma. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Dokkyo Medical Society |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2436-522X |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12941861 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.51040/dkmj.2022-054 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
DKMJ-2-1-10.pdf (870 KB)
.png)
